26. HTLV-1関連脊髄症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 29 / 薬物数 : 47 - (DrugBank : 29) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 119
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
Bortezomib
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Ciclosporin
Imperial College London
2006 Phase 2/Phase 3 NCT00773292 United Kingdom;
Costicosteroids
University of Sao Paulo
2008 Phase 3 NCT00681980 Brazil;
Cyclophosphamide
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Doxorubicin
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Doxorubicin Hydrochloride
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Doxorubicin hydrochloride
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Etoposide
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Filgrastim
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Hu MiK-Beta-1
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 1 NCT00076843 United States;
KW-0761
Kyowa Hakko Kirin Co., Ltd.
2017 Phase 3 JPRN-JapicCTI-173608 -
Kyowa Kirin Co., Ltd
2017 Phase 3 JPRN-JMA-IIA00324 Japan;
KW-0761 0.3 mg/kg IV
Kyowa Kirin Co., Ltd.
2017 Phase 3 NCT03191526 Japan;
Lamivudine
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Lenalidomide
Columbia University
2010 Phase 2 NCT01274533 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
MT-3921
Mitsubishi Tanabe Pharma Corporation
2022 Phase 1 NCT05240612 -
Methylprednisolone
St. Marianna University School of Medicine Hospital
2016 Phase 2,3 JPRN-UMIN000023798 Japan;
2016 - JPRN-UMIN000024086 Japan;
Mogamulizumab
Japan Agency for Medical Research and Development
2015 Phase 1 JPRN-UMIN000016683 Japan;
Kyowa Hakko Kirin Co., Ltd.
2017 Phase 3 JPRN-JapicCTI-173608 -
Nivolumab
Mayo Clinic
2017 Phase 2 NCT03075553 United States;
National Cancer Institute (NCI)
2017 Phase 2 NCT02631746 United States;
Pentosan polysulfate
ReqMed Company, Ltd
2014 Phase 2 JPRN-UMIN000015587 Japan;
Pentoxifylline
Hospital Universitário Professor Edgard Santos
2009 Phase 3 NCT01472263 Brazil;
Prednisolone
St. Marianna University School of Medicine Hospital
2016 Phase 2,3 JPRN-UMIN000024085 Japan;
2016 Phase 2,3 JPRN-UMIN000023798 Japan;
2016 - JPRN-UMIN000024086 Japan;
Prednisone
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Propantheline Bromide
Hospital Universitário Professor Edgard Santos
2012 Phase 1 NCT01640002 Brazil;
Raltegravir
National Institute of Neurological Disorders and Stroke (NINDS)
2013 Early Phase 1 NCT01867320 United States;
Washington University School of Medicine
2012 Phase 2 NCT01620736 United States;
2010 Phase 1/Phase 2 NCT01000285 United States;
Raltegravir and Zidovudine
Universidad Peruana Cayetano Heredia
2017 Early Phase 1 NCT02655471 Peru;
Recombinant human interferon beta-1a
National Institute of Neurological Disorders and Stroke (NINDS)
1998 Phase 2 NCT00001785 United States;
Recombinant interferon alfa
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Tamibarotene
St. Marianna University School of Medicine
2011 Phase 2/Phase 3 NCT01343355 Japan;
Teriflunomide
National Institute of Neurological Disorders and Stroke (NINDS)
2021 Phase 1/Phase 2 NCT04799288 United States;
Valproic acid
University of Sao Paulo
2008 Phase 3 NCT00681980 Brazil;
Valproid acid plus corticosteroids
University of Sao Paulo
2008 Phase 3 NCT00681980 Brazil;
Vincristine
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Vincristine Sulfate
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Vincristine sulfate
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Zidovudine
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Zidovudine/lamivudine
Imperial College London
1999 Phase 2/Phase 3 NCT00272480 United Kingdom;
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Ciclosporin
Imperial College London
2006 Phase 2/Phase 3 NCT00773292 United Kingdom;
Costicosteroids
University of Sao Paulo
2008 Phase 3 NCT00681980 Brazil;
Cyclophosphamide
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Doxorubicin
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Doxorubicin Hydrochloride
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Doxorubicin hydrochloride
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Etoposide
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Filgrastim
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Hu MiK-Beta-1
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 1 NCT00076843 United States;
KW-0761
Kyowa Hakko Kirin Co., Ltd.
2017 Phase 3 JPRN-JapicCTI-173608 -
Kyowa Kirin Co., Ltd
2017 Phase 3 JPRN-JMA-IIA00324 Japan;
KW-0761 0.3 mg/kg IV
Kyowa Kirin Co., Ltd.
2017 Phase 3 NCT03191526 Japan;
Lamivudine
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Lenalidomide
Columbia University
2010 Phase 2 NCT01274533 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
MT-3921
Mitsubishi Tanabe Pharma Corporation
2022 Phase 1 NCT05240612 -
Methylprednisolone
St. Marianna University School of Medicine Hospital
2016 Phase 2,3 JPRN-UMIN000023798 Japan;
2016 - JPRN-UMIN000024086 Japan;
Mogamulizumab
Japan Agency for Medical Research and Development
2015 Phase 1 JPRN-UMIN000016683 Japan;
Kyowa Hakko Kirin Co., Ltd.
2017 Phase 3 JPRN-JapicCTI-173608 -
Nivolumab
Mayo Clinic
2017 Phase 2 NCT03075553 United States;
National Cancer Institute (NCI)
2017 Phase 2 NCT02631746 United States;
Pentosan polysulfate
ReqMed Company, Ltd
2014 Phase 2 JPRN-UMIN000015587 Japan;
Pentoxifylline
Hospital Universitário Professor Edgard Santos
2009 Phase 3 NCT01472263 Brazil;
Prednisolone
St. Marianna University School of Medicine Hospital
2016 Phase 2,3 JPRN-UMIN000024085 Japan;
2016 Phase 2,3 JPRN-UMIN000023798 Japan;
2016 - JPRN-UMIN000024086 Japan;
Prednisone
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Propantheline Bromide
Hospital Universitário Professor Edgard Santos
2012 Phase 1 NCT01640002 Brazil;
Raltegravir
National Institute of Neurological Disorders and Stroke (NINDS)
2013 Early Phase 1 NCT01867320 United States;
Washington University School of Medicine
2012 Phase 2 NCT01620736 United States;
2010 Phase 1/Phase 2 NCT01000285 United States;
Raltegravir and Zidovudine
Universidad Peruana Cayetano Heredia
2017 Early Phase 1 NCT02655471 Peru;
Recombinant human interferon beta-1a
National Institute of Neurological Disorders and Stroke (NINDS)
1998 Phase 2 NCT00001785 United States;
Recombinant interferon alfa
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Tamibarotene
St. Marianna University School of Medicine
2011 Phase 2/Phase 3 NCT01343355 Japan;
Teriflunomide
National Institute of Neurological Disorders and Stroke (NINDS)
2021 Phase 1/Phase 2 NCT04799288 United States;
Valproic acid
University of Sao Paulo
2008 Phase 3 NCT00681980 Brazil;
Valproid acid plus corticosteroids
University of Sao Paulo
2008 Phase 3 NCT00681980 Brazil;
Vincristine
Washington University School of Medicine
2010 Phase 1/Phase 2 NCT01000285 United States;
Vincristine Sulfate
National Cancer Institute (NCI)
2020 Phase 1 NCT04301076 United States;
Vincristine sulfate
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Zidovudine
AIDS Malignancy Consortium
2002 Phase 2 NCT00041327 United States;
Zidovudine/lamivudine
Imperial College London
1999 Phase 2/Phase 3 NCT00272480 United Kingdom;